Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Appointed director
Director departure

NANOMIX Corp (BTHE) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
01/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "OFFER LETTER FOR CHRIS HETTERLY, DATED NOVEMBER 15, 2022",
"Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer"
11/10/2022 8-K Quarterly results
09/09/2022 8-K Appointed a new director
Docs: "Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors"
07/29/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "OFFER LETTER, DATED JULY 21, 2022",
"Natalya Rudman Crescendo Communications, LLC Email:"
05/10/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "OFFER LETTER, DATED FEBRUARY 28, 2022",
"Nanomix Appoints Vidur Sahney as Chief Operating Officer"
03/24/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "NANOMIX CORPORATION CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK The undersigned, David Ludvigson, does hereby certify that: 1. He is the Chief Executive Officer, of Nanomix Corporation, a Delaware corporation . 2. The Corporation is authorized to issue up to 5,000,000 shares of preferred stock, of which 2,150,000 have been issued. 3. The following resolutions were duly adopted by the board of directors of the Corporation : WHEREAS, the Certificate of Incorporation of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 5,000,000 shares, $0.001 par value per share, issuable from time to time in one or more series; WHEREAS, the Board of Directors is authorized to fix the dividend rig...",
"FORM OF WARRANT, DATED MARCH 23, 2022",
"SECURITIES PURCHASE AGREEMENT, DATED MARCH 23, 2022",
"CONSENT, AMENDMENT AND WAIVER, DATED MARCH 22, 2022"
03/02/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/05/2021 8-K Investor presentation
Docs: "INVESTOR PRESENTATION, OCTOBER 2021"
11/05/2021 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BUSINESS OF THE COMPANY",
"RISK FACTORS OF THE COMPANY"
09/10/2021 8-K Quarterly results
08/27/2021 8-K/A Quarterly results
06/29/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
02/02/2021 8-K Quarterly results
05/15/2020 8-K Quarterly results
04/14/2020 8-K Other Events
01/23/2020 8-K Changes in Registrant's Certifying Accountant
01/10/2020 8-K Resignation/termination of a director
12/06/2019 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from Liggett & Webb P.A"
09/25/2019 8-K Resignation/termination of a director
12/06/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/02/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "License Agreement between Boston Therapeutics, Inc. and Level Brands, Inc."
06/14/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Promissory Note"
06/01/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Boston Therapeutics, Inc. Investor Presentation"
04/30/2018 8-K/A Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "Audited Financial Statements of CureDM Group, LLC for the years ended December 31, 2017 and 2016",
"Pro-Forma Financial Information"
02/12/2018 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "Form of Contribution Agreement between Boston Therapeutics, Inc., CureDM Group, LLC and the members of CureDM Group Holdings, LLC",
"Executive Retention Agreement between Boston Therapeutics, Inc. and Loraine Upham"
02/12/2018 8-K/A Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
11/01/2017 8-K/A Quarterly results
08/22/2017 8-K Quarterly results
06/19/2017 8-K Form 8-K - Current report
05/02/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy